|
End-of-day quote
Nasdaq
29/09/2026
|
5-day change | 1st Jan Change | ||
| 1.950 USD | -1.02% |
|
-2.50% | -78.41% |
Company Valuation: enGene Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: October | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | 451.1 | 369.1 | 134 | - | - |
| Change | - | - | -18.18% | -63.69% | - | - |
| Enterprise Value (EV) 1 | - | 236 | 190.7 | -63.85 | -7.277 | 9.446 |
| Change | - | - | -19.19% | -133.49% | 88.6% | 229.8% |
| P/E | -0.14x | -6.06x | -3.15x | -1.08x | -1.26x | -1.87x |
| PBR | - | 1.65x | 2.2x | 0.73x | 1.28x | 1.73x |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.1x | 0.1x |
| Capitalization / Revenue | - | - | - | - | 21.7x | 3.71x |
| EV / Revenue | - | - | - | - | -1.18x | 0.26x |
| EV / EBITDA | - | -3.81x | -1.55x | 0.52x | 0.07x | -0.08x |
| EV / EBIT | - | -3.79x | -1.55x | 0.5x | 0.06x | -0.08x |
| EV / FCF | - | - | -1.89x | 0.46x | 0.05x | -0.06x |
| FCF Yield | - | - | -52.8% | 217% | 2,072% | -1,541% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -151.2 | -1.46 | -2.29 | -1.826 | -1.57 | -1.061 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 6.17 | 36.1 |
| EBITDA 1 | - | -61.97 | -122.7 | -121.7 | -108.8 | -125.6 |
| EBIT 1 | - | -62.3 | -123.2 | -126.6 | -124.2 | -112.1 |
| Net income 1 | -99.92 | -55.14 | -117.3 | -124.1 | -121.4 | -112.5 |
| Net Debt 1 | - | -215.2 | -178.4 | -197.9 | -141.3 | -124.6 |
| Reference price 2 | 21.695 | 8.850 | 7.210 | 1.980 | 1.980 | 1.980 |
| Nbr of stocks (in thousands) | - | 50,974 | 51,192 | 67,016 | - | - |
| Announcement Date | 29/01/24 | 19/12/24 | 22/12/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.1x | - | 0.52x | -.--% | 134M | |
| 21.73x | 7.77x | 15.61x | 1.37% | 74.46B | |
| 31.25x | 9.01x | 28.06x | 0.04% | 60.14B | |
| 33.64x | 6.03x | 18.07x | 0.97% | 48.15B | |
| 34.63x | 3.34x | 14.4x | -.--% | 44.25B | |
| -21.16x | 229.18x | -22.81x | -.--% | 43.99B | |
| 47.94x | 5.54x | 30.43x | -.--% | 41.61B | |
| 26.89x | 7.76x | 19.96x | 0.42% | 29.97B | |
| 33.91x | 7.26x | 18.84x | -.--% | 29.31B | |
| -70.02x | 13.44x | -68.51x | -.--% | 24.93B | |
| Average | 13.77x | 32.15x | 5.46x | 0.28% | 39.69B | |
| Weighted average by Cap. | 19.57x | 31.88x | 10.23x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ENGN Stock
- Valuation enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
